D.A. Davidson & Co. Recursion Pharmaceuticals, Inc. Transaction History
D.A. Davidson & Co.
- $12 Billion
- Q3 2024
A detailed history of D.A. Davidson & Co. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, D.A. Davidson & Co. holds 114,039 shares of RXRX stock, worth $704,761. This represents 0.01% of its overall portfolio holdings.
Number of Shares
114,039
Previous 107,534
6.05%
Holding current value
$704,761
Previous $806,000
6.82%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding RXRX
# of Institutions
286Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$203 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$156 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$150 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$107 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$95.1 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.12B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...